-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Neutral on RxSight, Lowers Price Target to $10

Benzinga·02/26/2026 16:45:34
Listen to the news
Piper Sandler analyst Adam Maeder maintains RxSight (NASDAQ:RXST) with a Neutral and lowers the price target from $11 to $10.